Page last updated: 2024-12-07
1,(n2)-ethenoguanine
Description
You're likely referring to **1-(N2-ethenoguanine)**, also known as **ε-guanine** or **ethenoguanine**.
Here's a breakdown:
**What it is:**
* **Structure:** 1-(N2-ethenoguanine) is a modified guanine base, a component of DNA and RNA. It's formed by the addition of an ethano bridge between the N2 and C8 positions of guanine.
* **Formation:** This modification arises due to exposure to various environmental mutagens, including vinyl chloride, acetaldehyde, and other reactive aldehydes.
**Importance in Research:**
1. **Carcinogenesis and Mutagenesis:**
* 1-(N2-ethenoguanine) is a **mutagenic lesion**, meaning it can cause changes in DNA sequence. It can lead to G:C to A:T transitions, which are associated with various cancers.
* This modification is found in both human and animal tissues and is linked to various types of cancers, including liver, bladder, lung, and colon cancer.
2. **Biomarker of Exposure:**
* The presence of 1-(N2-ethenoguanine) in DNA can be used as a **biomarker** to detect exposure to environmental mutagens. This helps researchers study the link between exposure and disease risk.
3. **DNA Repair Mechanisms:**
* Understanding how cells repair 1-(N2-ethenoguanine) lesions is crucial for developing strategies to prevent cancer. Researchers are investigating DNA repair pathways involved in removing this modification.
4. **Drug Development:**
* The study of 1-(N2-ethenoguanine) can contribute to the development of new drugs that target the formation of this lesion or enhance its repair mechanisms.
**Overall:**
1-(N2-ethenoguanine) is a significant area of research due to its role in mutagenesis, carcinogenesis, and the development of cancer prevention strategies. It's a key player in understanding the impact of environmental mutagens on human health.
1,(N2)-ethenoguanine: formed from 2-halooxiranes; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
1,N(2)-ethenoguanine : A nucleobase analogue obtained by addition of an etheno group across positions 1 and N2 of guanine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 124322 |
CHEBI ID | 134096 |
SCHEMBL ID | 8148622 |
SCHEMBL ID | 1576524 |
MeSH ID | M0226958 |
Synonyms (15)
Synonym |
1,(n2)-ethenoguanine |
1,n(2)-ethenoguanine |
56287-13-9 |
1,n(2)-epsilong |
1,4-dihydro-9h-imidazo[1,2-a]purin-9-one |
CHEBI:134096 |
1,4-dihydroimidazo[1,2-a]purin-9-one |
1,4-dihydro-9h-imidazo(1,2-a)purin-9-one |
9h-imidazo(1,2-a)purin-9-one, 1,4-dihydro- |
1,n2-epsilong nucleobase |
SCHEMBL8148622 |
SCHEMBL1576524 |
DTXSID60204825 |
epsilong |
3,9-dihydro-9-oxo-5h-imidazo[1,2-a]purine |
Drug Classes (2)
Class | Description |
imidazopurine | |
nucleobase analogue | A molecule that can substitute for a normal nucleobase in nucleic acids. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (14)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (21.43) | 18.2507 |
2000's | 8 (57.14) | 29.6817 |
2010's | 1 (7.14) | 24.3611 |
2020's | 2 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.85
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 11.85 (24.57) | Research Supply Index | 2.77 (2.92) | Research Growth Index | 4.62 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 15 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |